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Abstract: Therapeutic advancements in the treatment of various ocular diseases is often linked to the
development of efficient drug delivery systems (DDSs), which would allow a sustained release while
maintaining therapeutic drug levels in the target tissues. In this way, ocular tissue/cell response can
be properly modulated and designed in order to produce a therapeutic effect. An ideal ocular DDS
should encapsulate and release the appropriate drug concentration to the target tissue (therapeutic
but non-toxic level) while preserving drug functionality. Furthermore, a constant release is usually
preferred, keeping the initial burst to a minimum. Different materials are used, modified, and
combined in order to achieve a sustained drug release in both the anterior and posterior segments of
the eye. After giving a picture of the different strategies adopted for ocular drug release, this review
article provides an overview of the biomaterials that are used as drug carriers in the eye, including
micro- and nanospheres, liposomes, hydrogels, and multi-material implants; the advantages and
limitations of these DDSs are discussed in reference to the major ocular applications.
Keywords: ocular biomaterials; drug delivery; polymers; cell-biomaterial interaction
1. Introduction
Ocular diseases can be induced by a number of factors and affect both the anterior and the
posterior segment of the eye. The most common pathologies of the anterior segment are inflammatory
diseases such as blepharitis, conjunctivitis, dry eye syndrome, and uveitis [1]. Diseases of the posterior
segment typically comprise some chronic pathologies, the incidence of which significantly increased
over recent years due to the increase of the average life expectancy [1]. These pathologies include
choroidal neovascularization (CNV) following age-related macular disease (AMD), diabetic retinopathy
retinal vein occlusion, macular edema, and glaucoma. When left untreated, these diseases of the
posterior segment can lead to severe visual complications including dramatic visual deficiency and
even blindness, with an obvious impact on the patient’s quality of life and additional costs for society.
It was estimated that, in the early 2000s, there were 160 million people suffering from an important
visual deficiency worldwide and 37 million totally blind patients [2]. A more recent study published
in 2015 reported that there were 216 million people having a moderate to severe visual deficiency
and 12.9 to 65.4 million blind patients [3]. Projections for 2020 indicate an increase to 237 million and
70.9 million people suffering from partial and complete blindness, respectively [3].
In most cases, the treatment of chronic ocular diseases require periodic application of drugs.
The frequency, duration, and route of application of these drug-based treatments vary depending
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on the specifics of the disease, as well as the pharmacological and pharmacokinetic properties of the
molecule being delivered. For example, the diseases of the posterior segment like AMD can be treated
by intravitreal injections. Before 1999, fewer than 3000 intravitreal injections were delivered in the
United States annually; this number grew to one million in 2008 and over four million in 2013, rising
further with an increased trend [3]. This witnesses how the field of ocular drug release is significant in
modern society and clinics.
The eye offers multiple entry routes through which ocular drugs may be delivered [4–7]. The
topical route is the most common route of drug administration for the ocular surface and anterior
segment including cornea, conjunctiva, and anterior chamber [8]. This involves the easy self-application
of drug-containing solutions/suspension; however, it was estimated that less than 5% of drug can
actually reach the anterior segment due to the resistive properties of corneal barrier [9]. Therefore,
there is also the possibility of injecting the drug through into the subconjunctival space or directly
inside the anterior chamber in order to increase the drug concentration in the target organ.
The topical route can also be used to treat posterior segment diseases, although other strategies
are typically preferred and more efficient, including systemic, periocular (injections that are carried out
in the periocular area under the Tenon’s capsule), and intravitreal (within the vitreous) administration.
The latter two are the most commonly used clinically.
The therapeutic efficacy of drugs is strongly related to the pharmacological characteristics of
the molecule being delivered, as well as to the route of administration and the limiting barriers to
drug perfusion at the tissue level. Each delivery route has its own advantages and disadvantages.
For example, the topical route has the advantage of avoiding a direct contact/physical intervention on
the eyeball and is an easy strategy to treat various ocular disorders needing repetitive administration,
such as glaucoma, which is the first cause of irreversible blindness worldwide and needs chronic
treatment [10]. Glaucoma therapy is mainly topical by means of ophthalmic solutions to be instilled
daily in the affected eye for very long periods of time, even for a lifetime. However, the therapeutic
efficacy of the topical administration route almost entirely depends on the patient’s co-operation,
which may be suboptimal and difficult to control, and the drug can be lost by drainage of the instilled
solution through tears. In order to overcome these problems, miniaturized implants were recently
proposed for aqueous humor drainage and local release of hypotonic drugs.
In the attempt of providing feasible and more effective alternatives to many of the current therapies
for the anterior and posterior segment of the eye, new biomaterials and systems were developed such
as nano-emulsions, hydrogels, and vesicular systems (liposomes) [11–16]. These biomaterials typically
belong to the class of polymers, which are soft and well-tolerated by ocular tissues in a number of
surgical and non-surgical applications [17–20]. Controlled drug delivery systems (DDSs) are very
appropriate in those cases where a repeated dosing or injection is required. The goal of DDSs is to
increase periods of ocular drug contact and overall drug delivery by bypassing the ocular tissues that
act as limiting barriers to drug perfusion [21,22]. The targeted and prolonged release of ocular drugs is
a rapidly evolving field due to the advent of new biomaterials that are being developed in a context of
continuous research making impressive progress in recent years.
2. A Short Overview of Eye Anatomy
The eye is an organ of great complexity. It plays a key role in the visual process as it is the receptor
of optical information that is then processed by the retina and transmitted to the brain by means of the
optic nerve [17].
An average adult human eye is roughly spherical and measures approximately 24 mm in diameter.
The eye lies in the cavity of the bony orbit, which acts as a mechanical protector preventing trauma,
and it is anteriorly covered by the eyelids that are responsible for producing and distributing tears
over the eyeball surface while regulating the amount of light accessing the eye.
The eyeball consists of three tunics of distinct structure (Figure 1): (i) the outermost white fibrous
membrane is the sclera, with its clear anterior part, the cornea, which acts as the eye’s outermost
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lens; (ii) the middle vascular tunic, which encompasses the choroid, the iris, and the ciliary body;
(iii) the interior nervous membrane and the retina. There are two fluid media within the eyeball: the
aqueous humor and the vitreous body. These are separated by the crystalline lens and its suspensory
ligaments. The aqueous humor is a transparent fluid secreted by the ciliary processes into the anterior
and posterior chambers, and it provides nutrition to the areas lacking blood vessels (i.e., the lens and
the cornea). The vitreous body is a gelatinous substance that gives the eye structural support and fills
the space between the lens and the retina, which processes the light through a layer of photoreceptor
cells. The eye is schematically illustrated in Figure 1, and a concise description of its main components
and relative functions is provided in Table 1.
Each eye has six extraocular muscles (EOMs), functioning as antagonistic pairs. These muscles
are responsible for holding the eye steady or moving it along three different axes: horizontal, either
toward the nose (adduction) or away from the nose (abduction); vertical, either upward or downward;
and torsional—movements that rotate the top of the eye toward the nose (intorsion) or away from
the nose (extorsion). The EOMs originate in the posterior orbit, are attached to the sclera, and are
enveloped together with the eyeball and the optic nerve by the Tenon’s capsule to form a cone-shaped
unit within the bony orbit. Tenon’s capsule aids in suspending the orbital structures and acts as an
extraocular muscle pulley.
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Figure 1. Schematic illustration of the eye anatomy. Reproduced from Reference [17]. 
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The anterior, transparent part of the eye that covers the pupil and iris. It provides most of 
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Ocular 
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Two compartments that are filled with aqueous fluid. The anterior chamber is the space 
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Iris 
The pigmented membrane that gives the eye its color; it lies between the cornea and the 
crystalline lens and separates the anterior chamber from the posterior chamber. Its main 
purpose is to block excess light from entering the eye and to control the iris opening or 
“pupil” for differing amounts of ambient light.  
Aqueous 
humor 
A transparent fluid filling the anterior and posterior chambers. It provides nutrition to the 
areas lacking blood vessels (i.e., the crystalline lens and the cornea). 
Crystalline 
lens 
Transparent, biconvex structure located behind the iris; it is responsible for additional 
power for focusing light onto the retina. 
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Table 1. Components of the eye and their functions.
Component Function
Cornea The anterior, transparent part of the eye that covers the pupil and iris. It providesmost of the eye’s focusing power (about 2/3).
Ocular chambers
Two compartments that are filled with aqueous fluid. The anterior chamber is the
space between the cornea and the iris, whereas the smaller posterior chamber is
between the iris and the lens.
Iris
The pigmented membrane that gives the eye its color; it lies between the cornea and
the crystalline lens and separates the anterior chamber from the posterior chamber.
Its main purpose is to block excess light from entering the eye and to control the iris
opening or “pupil” for differing amounts of ambient light.
Aqueous humor A transparent fluid filling the anterior and posterior chambers. It provides nutritionto the areas lacking blood vessels (i.e., the crystalline lens and the cornea).
Crystalline lens Transparent, biconvex structure located behind the iris; it is responsible for additionalpower for focusing light onto the retina.
Tenon’s capsule External to the sclera, it is a membranous structure that envelopes the extraocular eyemuscles, as well as the eyeball and optic nerve.
Sclera
Opaque, fibrous outer tunic of the eye mainly composed of collagen. It holds together
the contents of the eye and contains openings and canals for the vessels and nerves
entering and exiting the eye.
Vitreous humor Gel-like substance located in the posterior portion of the eye, filling in the areabetween the lens and the retina.
Choroid Rich in blood vessels, provides nutrition to the retina.
Retina
Multilayered sensory tissue of the posterior eyeball onto which light entering the eye
is focused, forming a reversed and inverted image. It contains photosensitive
receptor cells, the rods and cones, which are capable of converting light into nerve
impulses that are conducted and further relayed to the brain via the optic nerve.
Optic nerve Structure at the back of the eye responsible for carrying nerve impulses from theretina to different areas of the brain.
Conjunctiva The mucous membrane covering the anterior sclera and the posterior aspect of theeyelids.
Extraocular muscles
(EOMs)
Six muscles which control the movement of the eye and are responsible for
movements along three different axes: horizontal, vertical, and torsional. Horizontal
movements are controlled entirely by the medial and lateral rectus muscles. Vertical
movements require the coordinated action of the superior and inferior rectus muscles,
as well as the oblique muscles. The oblique muscles are also primarily responsible for
torsional movements.
3. Strategies of Ocular Drug Administration
Various strategies can be applied to provide a pharmacological therapy to ocular tissues and
structures. The routes of administration of drugs to the anterior or posterior segments of the eye
are topical, intracameral (in the anterior chamber), transcleral/periocular, intravitreal, suprachoroidal
(seldom), and systemic.
3.1. Topical Route
The topical route is the most commonly used approach in current clinical practice, both in hospital
and in home therapy, due to its ease and non-invasiveness. The drug is provided in the form of eye
drops or ointment that can be useful in the treatment of many disorders of the ocular surface and
anterior segment.
Topical treatments used for anterior segment diseases must first pass through the corneal
epithelium, which exhibits a significant “barrier effect” to the penetration of drug molecules into the
tissue due to its hydrophobic characteristics [23]. Specifically, the corneal epithelium is lipophilic and
is the main barrier to the passage of hydrophilic drugs, while the hydrophilic stroma constitutes a
barrier to lipophilic substances. Another limiting factor for topical administration is the molecular
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weight of the drug as it was estimated that only small molecules (less than 1 kDa) can easily pass
through the corneal endothelium [24].
Under normal conditions, a human eye can host 25–30 µL of an ophthalmic solution; further
reductions in the amount that is absorbed are due to blinking, i.e., the drainage of tears through the
outflow pathways which causes systemic absorption via the nasal mucosa and the gastrointestinal
tract [25].
In order to improve topical absorption and, hence, the bioavailability of drugs in intraocular
tissues, research is ongoing to find suitable drug carriers that increase the time of contact with the
ocular surface and/or the passage of drugs through ocular barriers [26,27]. It is interesting to point out
that only 1–10% of the instilled dose of drug is absorbed at the ocular level and only about 1% reaches
the aqueous humor [28].
3.2. Intracameral Route
Intracameral injection provides high drug concentrations in the anterior chamber. This route is
commonly used for the anesthesia of the eyeball, the prevention of endophthalmitis during ocular
surgery (especially cataract), and the treatment of inflammations of the anterior segment [29]. The
most widely used antibiotics in such a strategy are vancomycin, moxifloxacin, and cephalosporins.
It was previously shown that intracameral delivery of dexamethasone may result in a decrease in
skin hypopigmentation, extraocular muscle atrophy, and subdermal fat atrophy [30]. However, some
drawbacks have to be accounted for this route including toxic anterior segment syndrome (TASS),
which is a consequence of introducing a noninfectious substance to the anterior segment [31].
3.3. Transcleral/Periocular Route
The sclera has a fibrous structure and exhibits a large surface (about 95% of the total surface
of the eye) which offers less resistance to the diffusion of substances compared to the cornea [32].
The transcleral/periocular approach takes advantage of this feature and allows obtaining a greater
permeation of the drug. However, this administration route is recommended only for drugs that have
a molecular weight lower than about 70 kDa.
3.4. Intravitreal Route
Intravitreal injections are the most invasive way to obtain therapeutic concentrations of the drug in
the posterior segment. For this reason, serious complications are possible, including cataracts, vitreous
hemorrhage, retinal detachment, and endophthalmitis [33]. Surgical care and the use of accurate
sterilization protocols minimize the incidence of such complications. This administration route is used
in the therapy of exudative senile macular degeneration, where anti-vascular endothelial growth factor
(VEGF) drugs (e.g., bevacizumab, ranibizumab, and aflibercept) are injected every 30–60 days to reach
and maintain a sustained therapeutic concentration [34]. The high cost and obvious impact of this
strategy on the patient led to the development of minimally invasive DDSs that are positioned inside
the eyeball in order to reduce the frequency of intravitreal injections.
Apart from being used to supply anti-VEGF agents, the intravitreal injection method typically
provides corticosteroids and antibiotics; intravitreal solid implants for long-term drug release include
Ozurdex (Allergan, Irvine, CA, USA) and Illuvien (Alimera Sciences, Alpharetta, GA, USA).
3.5. Sub-Retinal Route
The sub-retinal space provides a good space for injection of different drugs and therapeutic
substances (e.g., gene therapy, cell therapy) to treat vitreoretinal diseases [35]. In this route, drugs
administrated are in direct contact with the plasma membrane of the photoreceptors, retinal pigment
epithelium (RPE), and subretinal blebs [36,37]. Due to its high precision and efficacy, the sub-retinal
route is considered as one of the most effective methods used for ocular drug delivery [38]. The
Bioengineering 2020, 7, 65 6 of 31
sub-retinal space can be typically accessed by the posterior trans-scleral route or trans-choroidal route
(passing through the choroid and Bruch’s membrane without penetrating the retina) [39–44].
3.6. Suprachoroidal Route
This strategy is relatively less common as compared to the other approaches. In a recent study,
Lewis et al. [45] developed an iTrack microcatheter system through which drug molecules, such
as triamcinolone acetonide (TA) and bevacizumab, can be released into the suprachoroidal space.
Patel et al. [46] in an experimental study on animal eyes used borosilicate microneedles to inject
boluses of drugs, as well as micro- and nanospheres, into the suprachoroidal space. Suprachoroidal
microneedles releasing triamcinolone acetonide are currently being studied to treat uveitis [47].
3.7. Systemic Route
This strategy may be applied when the other ones are discouraged or unfeasible due to the specific
clinical case, or when the other approaches would imply the local administration of too high doses of
drug, thus carrying the risk of toxic effects [48]. However, systemically administered drugs should
pass the blood–aqueous barrier at the level of the anterior segment and the blood–retinal barrier at the
level of the posterior segment. The latter has tight junctions that do not allow several drug molecules
to enter the posterior segment. Therefore, therapeutic concentrations of drugs in the posterior segment
are better obtained locally rather than through systemic administration [49]. Furthermore, systemic
drug delivery may be associated with immunological and metabolic side effects [50].
4. Biomaterials and Implants for the Ocular Release of Therapeutics
Over the last few years, a number of implantable systems were designed and tailored to release
therapeutics into the eye to elicit an appropriate response by ocular tissues. Organic biomolecules
(e.g., antibiotics, anti-inflammatory, or anti-proliferative drugs) and, more rarely, therapeutic metallic
cations were experimented and/or clinically tested for this purpose.
4.1. Therapeutic Ion Release from Orbital Implants and Ocular Prostheses
Orbital implants are introduced into the patient’s orbit after removal of the eyeball due to
serious trauma or ocular cancer requiring enucleation [51]. The most commonly used options include
hydroxyapatite, polyethylene, or alumina porous spheres, which are “buried” under the patient’s
conjunctiva and are postoperatively invaded by fibrovascular tissue [52,53]. These implants are then
covered by external polymethylmethacrylate (PMMA) ocular prostheses that are placed over the
conjunctiva for aesthetic purposes [54].
A severe complication during surgery and in the mid-term is the risk of implant-related infections;
during the operation, the porous spheres are typically impregnated with antibiotic solutions that,
however, exhibit a burst release and are ineffective against late infections [55]. Baino et al. [56] tested
the antibacterial efficacy of composite coatings made up of silver nanoclusters embedded in a silica
matrix. These silver/silica coatings can be deposited on the orbital implant surface, as well as on the
posterior surface of the PMMA prosthesis in contact with the patient’s conjunctiva. The coatings were
mechanically well adherent to the substrate and revealed a potent antibacterial activity inhibiting the
growth of Staphylococcus aureus in vitro. The antiseptic action was related to the release of silver ions
that disrupt the bacterial membrane; interestingly, ion-based therapy was suggested as a promising
alternative to antibiotics as metallic ion release does not create the problem of bacterial resistance.
A similar approach, based on the deposition of an antiseptic layer, was reported by Ye et al. [57]
who coated porous hydroxyapatite orbital implants with copper-doped mesoporous bioactive glass
(MBG). This study aimed at synergistically combining the antibacterial effect of released copper ions,
which are able to kill bacteria via the generation of reactive oxygen species, lipid peroxidation, protein
oxidation, and DNA degradation [58], and ofloxacin, an antibiotic hosted inside the glass mesopores
(pore size within 3–5 nm). In vitro tests showed that copper-doped implants inhibited the viability of
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S. aureus and Escherichia coli (Figure 2); furthermore, since drug loading and release capacity was less
efficient in the samples with higher copper concentration, a predominant antiseptic effect of released
copper ions over antibiotic molecules was suggested [57].Bioengineering 2020, 7, 65 7 of 30 
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4.2. Microspheres and Nanospheres
Polymeric microspheres and nanospheres are among the most widely used DDSs for the release
of biomolecules due to the large availability of different materials that can be used in the transport of
therapeutics [65,66]. The size of microspheres is between 1 and 1000 µm while nanospheres are in the
range of 10 nm to 1 µm. Nanoparticles are drug transport systems in which the active substance is
dissolved or encapsulated or on which it is absorbed or attached. In general, they are small spheres
that offer a large specific surface area. Nanocapsules are small tanks with a central cavity surrounded
Bioengineering 2020, 7, 65 8 of 31
by a polymer membrane in which the drug molecules are dissolved in an oily core or adsorbed at
the core/shell interfacial surface. An ideal formulation of nanoparticles allows a prolonged release of
drugs and, hence, a long-term therapeutic effect.
Nanosystems are also useful for intravitreal injection because they delay drug clearance, thus
reducing the need for repeated injections and the risk of complications. The lipophilic–hydrophilic
optimization of the polymer–drug system is a key aspect. The polymers used for the preparation of
nanoparticles should exhibit biocompatibility and mucoadhesiveness, swelling properties, adequate
molecular weight, a degree of crosslinking, and bioavailability, which depends on the bioadhesion
characteristics of the polymer [25].
Synthetic polymers are widely used to synthesize microspheres and nanospheres as they are
biocompatible and biodegradable to by-products that can be metabolized by the human body, so
that no additional removal surgery is needed [67]. Drug release kinetics should be properly tailored
according to the purpose and duration of the therapy by changing the polymer composition. Micro-
and nanospheres have the ability to incorporate both hydrophilic and hydrophobic molecules, as
well as proteins, peptides, vaccines, and biological macromolecules. If copolymers are used, their
characteristics can be adapted for each specific use by modifying the polymer ratios and microstructures
and/or by applying strategies of surface functionalization [68].
4.2.1. Poly(lactic-co-glycolic) Acid
Poly(lactic-co-glycolic) acid (PLGA) is used in many therapeutic devices approved by the Food and
Drug Administration (FDA) due to its well-proven biodegradability and biocompatibility [69]. PLGA
is obtained by a ring-opening copolymerization reaction of cyclic homodimers (1,4-dioxane-2,5-dions)
of glycolic acid and lactic acid.
The catalysts which are commonly used in the synthesis of this polymer include tin
2-ethylhexanoate or aluminum isopropoxide. In the polymerization, the monomeric units (glycolic or
lactic acid) are bonded together in the PLGA macromolecules by ester bonds, thus obtaining a linear
aliphatic polyester as a product of polymerization.
PLGA is amorphous with a glass transition temperature within 40–60 ◦C and is soluble in most
organic solvents. PLGA properties can be properly tailored depending on the ratio between the
monomers; for example, the degradation time (or the persistence) and the mechanical properties can
be increased by increasing the amount of lactic acid. Due to its versatility, PLGA is used for making
a number of biomaterials, including surgical sutures (lactide:glycolide = 1:9), fixation devices, and
biodegradable micro-/nanoparticles for the controlled release of biomolecules such as proteins, small
interfering RNAs (siRNAs), and antigens, which can be administered in different ways (intramuscular
injections, inhalation, and oral ingestion) [70,71]. Gentile et al. [69] reported that the degradation of
PLGA micro- and nanospheres is mainly due to the ratio of lactic acid to glycolic acid. Persistence
time can vary from one week to two years depending on the ratio between the co-monomers and the
consequent degree of hydrophobicity and crystallinity [72].
The release of drugs from PLGA occurs in a dose-dependent manner and is influenced by the rate
of polymer degradation. The release profile often exhibits a three-stage pattern comprising an initial
burst followed by a constant release and a final drug burst [73,74]. Furthermore, a smaller particle
(from macro- to nanoscale) leads to faster degradation.
PLGA microspheres are mainly used for the release of biomacromolecules such as proteins,
deoxyribonucleic acid (DNA), ribonucleic acid (RNA), vaccines, and peptides [75].
PLGA carriers suffer from some limitations, including low to moderate efficiency of drug
encapsulation (less than 60% for microspheres and less than 30% for nanospheres), high initial drug
burst (20% to 50% of the encapsulated proteins are released in the first 24 h [76]), incomplete release
of trapped proteins [54,55], and creation of an acidic environment as a result of the degradation of
the hydrophobic part of the polymer. Low values of pH can lead to denaturation and aggregation of
proteins, as well as protein instability and, hence, incomplete release [77–80].
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4.2.2. PLGA/Polyethylene Glycol (PEG) Copolymers
Block copolymers of PLGA/polyethylene glycol (PEG) were developed in order to improve
the drug release capability of the PLGA microspheres. PEG is a polymer of ethylene glycol that is
synthesized via acid or basic catalysis. According to its molecular weight, PEG can be either liquid (low
molecular weight) or solid (molecular weight up to 106 Da) in the form of a crystalline polymer [81].
PEGs are biocompatible and are excreted from the body without being modified (they are not
very biodegradable); their clinical use is approved by FDA.
PEG carriers form a protective barrier around the drugs, enhancing the biomolecule durability
and stability. However, PEG was shown to have a low encapsulation efficiency of antibiotics and
proteins, thereby being suitable only for incorporating a limited set of biomolecules [73].
4.2.3. Copolymers with Gallic Acid
In the context of biomaterials for ocular DDSs, gallic acid (GA) was shown to play a very
important role in the in situ gelification of gelatin-G-poly(N-isopropylacrylamide) (GN) copolymers,
which combine biodegradable gelatin and thermally reactive poly(N-isopropylacrylamide) and are
typically used for the intracameral delivery of pilocarpine in glaucomatous patients [82]. Furthermore,
GA is known to have antioxidant activity [83]. Chou et al. [82] grafted GA on GN copolymers at
various redox reaction times by using a redox pair of ascorbic acid (AA) and hydrogen peroxide
as a radical initiator. By increasing the redox reaction time, the total antioxidant activity and the
reactive oxygen species (ROS) scavenging capacity against 2,2-diphenyl-1-picrylhydrazyl (DPPH)
radicals increased, as a result of the higher amount of GA grafted on the GN copolymers. The
physico-chemical properties of GNGA hydrogels were affected by the hydrophilic nature of the GA
molecules; specifically, the higher water-absorbing capacity and degradability were directly related to
the presence of GA grafts. Pilocarpine encapsulation also depended on the amount of GA grafts, and
in vitro drug release studies suggested a three-stage release mechanism, which includes initial burst,
diffusion, and polymer degradation. Injections of pilocarpine-loaded GNGA biomaterials into the
anterior chamber of glaucomatous rabbits led to a decrease of intraocular pressure (IOP) and pupil
diameter. At the end of the in vivo experiments, examination of corneal endothelium revealed that the
morphology of hexagonal cells was preserved, thus indicating the safety of the treatment. Biochemical
analyses of the rabbit’s aqueous humor also showed that increasing GA graft amounts increased the
total level of antioxidants and decreased the overall level of nitrite. Therefore, the potential suitability
of GNGA antioxidant hydrogels for the treatment of glaucoma was demonstrated; the grafting of small
antioxidant molecules (GA) facilitated proper changes of the physico-chemical properties, drug release
behavior and bioactivity of carrier materials.
4.2.4. Copolymers with Polysaccharides
Poly(N-acetyl-1,4-β-d-glucopiranosamina), commonly known as chitin, is a biodegradable
polysaccharide that can be combined with PLGA to modify and improve the functional characteristics
of the polymeric microspheres, such as degradation and drug release kinetics. The cleavage of the
β-glycosidic bond between the d-acetylglucosamine unit (chitin degradation) leads to faster weight
loss than PLGA degradation [67,72]. Chitin is more hydrophilic than PLGA; thus, degradation is
accelerated. The combined PLGA–chitin microspheres produce a particular release pattern with an
increase of the initial release rate of the drug followed by a prolonged period (several days) of slow and
constant delivery. Mi et al. reported the effect of chitin on the swelling ratio, which indirectly reflects
the crosslinking density of the polymer and the rate of degradation that is faster with a decreasing
content of chitin [67].
Alginate is another biodegradable polysaccharide that is used for the encapsulation and release of
a variety of biological agents, cells, DNA, and enzymes without altering their biological activity [84].
The incorporation of alginate into polymer-based microspheres was shown to reduce drug release
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discharges (by 1/6 and 1/3 if modified with 1.5% and 0.75% of alginate solution) [85]. Jay and
Salzman [86] highlighted how alginate increases the bioactivity and stability of the pro-angiogenic
protein VEGF. In a comparative study, Zheng et al. proposed the use of alginate–chitosan microspheres,
two hydrophilic protectors, to reduce the acidity of the environment that causes protein denaturation
when PLGA microspheres (used as a reference DDS) degrade [78]. Furthermore, this copolymeric
system demonstrated a reduced initial burst release (about 20%) and a higher encapsulation efficiency
of bovine serum albumin compared to PLGA alone [78].
4.2.5. Gelatin
Gelatin is a denatured protein derived from collagen (a constituent of the corneal tissue) by acid
or alkaline hydrolysis. The applicability of gelatin nanoparticles as ocular DDSs was investigated,
and the reported outcomes show promise. Moreover, gelatin can be applied in different forms (e.g.,
hydrogels) for the repair of various ocular diseases such as focal corneal wounds [87]. Gelatin
nanoparticles as a DDS show merits including appropriate compatibility to ocular compartments, very
low antigenicity, good mucoadhesive properties, good stability, effective lowering of the IOP, high
drug bioavailability, and a lack of irritation [88–90]. In 2016, Mahor et al. reported the use of cationic
gelatin nanoparticles loaded with moxifloxacin as an effective ocular DDS in the corneal layer [91]. The
prepared nanoformulations showed a controlled release of drug up to 12 h and potent antibacterial
activity against Staphylococcus aureus and Bacillus subtilis. The use of hybrid systems based on gelatin
was also suggested for effective ocular topical administration of drugs [92]; gelatin nanoparticles
loaded with timolol maleate were successfully included in a hydroxypropyl methylcellulose (HPMC)
carrier with the aim of reducing the high IOP in glaucoma [93]. In another work, mesoporous silica
nanoparticles were covered by pilocarpine-loaded gelatin (p/GM) and intracamerally injected into
the anterior chamber of rabbit eyes to extend the drug release time, improve ocular bioavailability,
and reduce the IOP (Figure 3) [94]. A high release percentage (50%) with a long-lasting release profile
(36 days) was observed in vitro; furthermore, in vivo data showed a successively reduction of IOP.
Looking at the existing literature, there is a relative paucity of studies using gelatin nanoparticle-based
DDSs for the ocular tissue, and researchers are encouraged to focus more on them.
Bioengineering 2020, 7, 65 10 of 30 
4.2.5. Gelatin  
Gelatin is a denatured protein derived from collagen (a constituent of the corneal tissue) by acid 
or alkaline hydrolysis. The applicability of gelatin nanoparticles as ocular DDSs was investigated, 
and the reported outcomes show promise. Moreover, gelatin can be applied in different forms (e.g., 
hydrogels) for the repair of various ocular diseases such as focal corneal wounds [87]. G latin 
nanoparticles as a DDS show merits including appropriate compatibility to ocular compartments, 
very low antigenicity, good mucoadhesive properties, good stability, effective lowering of the IOP, 
high drug bioavailability, and a lack of irritation [88–90]. In 2016, Mahor et al. reported the use of 
cationic gelatin nanoparticles loaded with moxifloxacin as an effective ocular DDS in the corneal layer 
[91]. The prepared nanoformulations showed a controlled release of drug up to 12 h and potent 
antibacterial activity against Staphylococcus aureus and Bacillus subtilis. The use of hybrid systems 
based on gelatin was also suggested for effective ocular topical administration of drugs [92]; gelatin 
nanoparticles loaded with timolol maleate were successfully included in a hydroxypropyl 
methylcellulose (HPMC) carrier with t e aim of red ing the high IOP in glauc ma [93]. In an ther 
work, mesoporous silica nanoparticles were covered by pilocarpine-loaded gelatin (p/GM) an  
intracamerally injected into the anterior chamber of rabbit eyes to extend the drug release time, 
improve ocular bioavailability, and reduce the IOP (Figure 3) [94]. A high release percentage (50%) 
with a long-lasting release profile (36 days) was observed in vitro; furthermore, in vivo data showed 
a successively reduction of IOP. Looking at the existing literature, there is a relative paucity of studies 
using gelatin nanoparticle-based DDSs for the ocular tissue, and researchers are encouraged to focus 
more on them.  
 
Figure 3. Schematic illustration showing synthesis of silica nanoparticles covered by pilocarpine-
loaded gelatin (p/GM) as an ocular drug delivery system (DDS) to decrease the intraocular pressure 
(IOP) through intracameral injection into the anterior chamber of rabbits’ eye. Reproduced with 
permission from Reference [94]. 
4.2.6. Chitosan 
Chitosan is a natural polysaccharide copolymer of chitin from crustacean shells, which is 
structurally composed of glucosamine and N-acetylglucosamine units [95]. To date, chitosan is used 
for various applications in ophthalmology, including contact lenses, solutions, coated nanocapsules, 
and micro/nanoparticles [96,97]. Chitosan showed the ability to accelerate corneal wound healing via 
Figure 3. Schematic illustration showing synthesis of silica nanoparticles covered by pilocarpine-loaded
gelatin (p/GM) as an ocul r drug delivery syst m (DDS) to decrease the intraocular pressure (IOP)
through intracameral injection into the anterior chamber of ra bits’ eye. Reproduc d with permission
from Reference [94].
Bioengineering 2020, 7, 65 11 of 31
4.2.6. Chitosan
Chitosan is a natural polysaccharide copolymer of chitin from crustacean shells, which is
structurally composed of glucosamine and N-acetylglucosamine units [95]. To date, chitosan is used
for various applications in ophthalmology, including contact lenses, solutions, coated nanocapsules,
and micro/nanoparticles [96,97]. Chitosan showed the ability to accelerate corneal wound healing
via inducing the migration of keratinocytes [98,99]. With regard to drug delivery applications,
chitosan offers some advantages including its favorable production cost–benefit ratio, biocompatibility,
and biodegradability. Specifically, anti-bacterial and antifungal activities, high mucoadhesiveness,
the ability to penetrate the corneal surface (via opening the tight junctions), and excellent ocular
tolerance make chitosan a suitable candidate for ophthalmic drug delivery [100,101]. Modified or
un-modified chitosan nanoparticles are widely used for delivery of a broad range of therapeutics (e.g.,
anti-inflammatory, anti-bacteria, and anti-glaucoma drugs) for managing ocular diseases [102–104].
In this regard, Li et al. used trimethyl chitosan (TMC)-coated lipid nanoparticles (LPNs) for improving
the ocular bioavailability of baicalein (BAI) [105]. The prepared formulation (TMC–BAI–LNPs) had a
particle size of 162.8 nm and a positive surface charge (zeta potential of 26.6 mV) with 90.65% drug
entrapment efficiency. The drug-loaded nanoparticles showed no ocular irritation in an animal model
(rabbits), and the area under the plasma concentration time curve (AUC) was 3.17-fold higher for
TMC–BAI–LNPs as compared to controls. The authors concluded that this system could overcome the
limited ocular bioavailability of BAI. It should be highlighted that there are several experimental studies
in which chitosan nanoparticles were used for ocular drug delivery in combination with other polymers
(PLGA, hyaluronan, and alginate) [106–108], polysaccharides (cyclodextrin and dextran) [109,110], and
lipid mixtures (e.g., lecithin) [111].
4.2.7. Other Polysaccharides
Polysaccharides including cellulose, alginate, pectin, and xanthan gum were previously reviewed
in the context of ocular drug delivery approaches [112]. Cellulose and its derivatives are recognized
as the first members of polysaccharides used in ophthalmology as topical ophthalmic dosage
forms [113]. Due to the water insolubility of pure cellulose, some of its derivatives (e.g., hydroxypropyl
methylcellulose (HPMC) and carboxy methyl cellulose (CMC)) are extensively used in treating
ocular-related diseases, for example, as eye drops [114,115]. Theses derivatives could also be combined
with other polymeric materials for potential use in ophthalmology [116,117]. It was pointed out that
cellulose-based macromolecules show the capability of improving the viscosity of formulations and,
thereby, may enhance the corneal residence time [118]. In 2019, Orasugh et al. assessed the effect of
cellulose nanocrystals (CNC) on drug loading efficacy of triblock poloxamer 407 copolymer (PM)-based
in situ hydrogels [119]. The authors aimed to attain a longer pre-corneal residence time and good
bioavailability of pilocarpine hydrochloride. For this purpose, a series of composite formulations were
developed including those without CNC (called M1) and others containing 0.8%, 1.0%, and 1.2% (w/v)
CNC (called M2, M3, and M4, respectively). The results showed an increase in gel strength along
with the sustained release of pilocarpine hydrochloride after addition of CNCs. Furthermore, the
cumulative percentages of pilocarpine hydrochloride release from the composites M1, M2, M3, and M4
were 87.26%, 52.89%, 40.43%, and 34.57%, respectively, at 420 min post-test, thus revealing the key role
of CNCs in modulating the drug release kinetics.
Alginate is another natural polysaccharide made of linear unbranched copolymers (1–4)-linked
β-d-mannuronic acid and (1–4)-linked α-l-guluronic acid. Biocompatibility, biodegradability, and ease
of chemical modification make alginate a suitable vehicle for delivery of a wide range of bioactive
molecules such as those used in ocular tissue repair [120,121]. Improved ocular bioavailability of various
types of drugs (e.g., lutein) is achievable via their administration by alginate and its composites [122].
Moreover, the use of alginate composites was successfully reported in the context of controlled drug
delivery for treating ophthalmological diseases and disorders, such as the posterior segment ocular
diseases [123,124]. In this regard, Khlibsuwan et al. recently reported the effectiveness of anticandidal
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activity of clotrimazole (CZ) loaded in calcium alginate (CA)–poloxamer (PLX) beads [125]. For this
purpose, blends of PLX188 or PLX407 into sodium alginate (SA) were added to form dispersions
and films and to characterize the PLX–CA beads for increasing the ocular bioavailability of CZ and
improving anticandidal delivery. The authors showed that the addition of 0.5% or 1% w/v PLX (PLX188
and PLX407) to CA could increase the entrapment efficiency of CZ in the beads. Moreover, PLX adding
resulted in an enhanced release of CX from the beads and subsequent better activity against Candida
albicans as compared to CA beads (Figure 4).Bioengineering 2020, 7, 65 12 of 30 
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Pectin is a complex renewable carbohydrate polymer found in the cell walls of plants and is mainly
formed of galactur nic acid units joined by α-(1→4) linkages [126]. Due to the high gel ing c pac ty,
pectin and its composites are w dely used in tissue engineering and drug delivery applications [127,128].
The usefulness of pectin in the trea ment of ocu ar ti sue diseases was pr viously doc mented; for
instance, Chan et al. prepared electrospun nanofibers made of pecti –polyhydroxyb tyrat (p c-PHB)
blended with PHB for retinal tissu engi e ring and show d that this c nstruct was a suitable
substrate f r human r tinal pigmented pithelium (ARPE-19) cells [129]. I order to further explore
the potential of pectin in ocular drug delivery, thiolated pectin nanoparticles were also synthesized by
using magnesium chloride as the ionic cross-linker [130]. The obtained data indicated that thiolated
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pectin (0.01% w/v) and magnesium chloride (0.01% w/v) led to achieving 237-nm particles and 94.6%
entrapment of timolol maleate as the model drug. Higher corneal permeation of timolol maleate
was observed in an ex vivo model of the excised goat cornea by administration of thiolated pectin
nanoparticles in comparison to the conventional solution dosage form. In another experimental
study, Dubey et al. prepared brinzolamide-loaded pectin–chitosan mucoadhesive nanocapsules via
the polyelectrolyte complex coacervation method for potential use as DDS in the management of
glaucoma induced in a rabbit eye model [131]. The particle size of pectin–chitosan was in the range
of 217.01 ± 0.21 to 240.05 ± 0.08 nm. The results of the in vitro release study showed early burst
release and subsequently sustained release of the drug for 8 h, which was significantly better than a
marketed formulation. The ex vivo corneal permeation test revealed that the drug-loaded particles
were able to cross through the cornea in a higher rate than the marketed product, resulting in a greater
IOP-lowering effect. Based on these results, the authors stated that this nano-formulation could be a
feasible evolution of conventional eye drops, thanks to its capability of improving the bioavailability
(via longer precorneal retention time) and providing sustained release of the drug. It should be
highlighted that the potential of pectin as a stabilizer for liposomal drug delivery systems was also
documented [132].
Xanthan gum is a negatively charged polysaccharide with interesting rheological and gelling
characteristics, and it was proposed for ophthalmic applications such as sustained drug release [133,134].
This polymer is also used as an additive to increase the drug release time in comparison to conventional
eye drops [135]. Biocompatibility assessments revealed that a fixed combination of 0.09% xanthan gum
and 0.1% chondroitin sulfate had no adverse effects on the anterior and posterior segments of a rabbit
model for 15 days [136]. In 2014, Amico et al. reported the anti-oxidant effect of 0.2% xanthan gum in
human corneal epithelial cells (HCE), as it was able to reduce the level of ROSs to negative control
values [137].
4.3. Liposomes
The term “liposome” derives from the Greek words “lypos” (fat) and “soma” (body), as liposomes
are composed of a lipid double layer, which is similar to a the phospholipidic cell membrane, and
cholesterol that surrounds an aqueous compartment [138]. If intravenously injected into an organism,
liposomes are conglobated by the cells of the reticuloendothelial system that degrades them, allowing
the release of the internal substances.
Therefore, liposomes can be used as vehicles for carrying many drugs and molecules, including
proteins, nucleotides, and plasmids, which can be encapsulated in this aqueous compartment [139].
The liposome membrane undergoes deformation under external loads without interrupting its
chemical or mechanical properties, thus allowing injection through small-size needles [138–140].
Fahmy et al. [141] recently demonstrated the efficacy of anti-glaucoma drugs contained in liposomes
that were subconjunctivally injected in an animal model. The diameter of liposomes typically ranges
from 50 nm to a few micrometers. Both hydrophilic and hydrophobic drugs can be encapsulated in the
aqueous cavity or introduced through the lipid membrane.
Advantages of using liposomes compared to the other drug administration route include the
ability of finely controlling the release kinetics, reducing the risk of toxic effects, and extending the
drug half-life [138–140]; furthermore, liposome exhibit an intrinsic affinity to hydrophobic biological
barriers such as the corneal epithelium, thus allowing drug passage.
Modifications of the liposomal surface with other proteins or polymers can provide extra
functionalities such as light activation or chemical activation that allow a more targeted and finely
controlled release. Verteporfin (Visudyne, Novartis, Switzerland) was the first liposome-based
formulation used for the photodynamic therapy of different types of neovascular AMD [142–144].
Lajavardi et al. observed an improved topical release of bevacizumab due to the modification of
the surface of the phosphatidylserine-based liposome by annexin A5, an anionic calcium-dependent
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phospholipid binding protein. Furthermore, the same research group used vasoactive intestinal
peptide (VIP)-encapsulating liposomes to treat uveitis in rats by intravitreal injection [145].
Limitations of liposomes include the relatively limited amount of transportable drug that can be
encapsulated, the need for caution during sterilization procedures, and the risk of interference with
vision (blurring effect) after intravitreal injections [146].
4.4. Hydrogels
Since their development in the 1960s, hydrogels were increasingly applied in many fields of
biomedicine, including DDSs, scaffolding for tissue reconstruction, and cell transplantation [147,148].
The three-dimensional structural network of cross-linked hydrogels protects therapeutic biomolecules
from immune reactions and degradation by enzymes. Hydrogels also provide a versatile mean to
finely control the drug release kinetics. Furthermore, some hydrogels (e.g., triblock PLGA copolymers)
can change their physical properties at different temperatures; in other words, they remain in solution
at low temperatures and assume a gelatinous consistency at body temperature [73].
In spite of these potentially attractive features, hydrogels also exhibit several disadvantages
including difficult sterilization [149,150], limited shelf life, risk of damage to biopharmaceuticals due to
chemical cross-linking reactions [151], risk of toxic effects caused by polymerization initiator residues
following polymerization [152], and difficult control of degradation kinetics and drug release due to
water absorption during swelling [153].
The use of hydrogels in the ophthalmic field is of great importance for the production of soft
contact lenses. In addition to correcting visual defects, hydrogel-based lenses were proposed as local
DDSs in order to extend the contact time between drug and ocular surface and minimize drug losses as
compared, for example, to topical administration. Studies conducted by Ribeiro et al. [154] led to the
synthesis of biomimetic poly(2-hydroxyethylmethacrylate) (pHEMA) hydrogels to be used as carriers
of carbonic anhydrase inhibitors for glaucoma treatment. pHEMA hydrogel exhibited a high affinity to
these inhibitors and allowed achieving a better control over release behavior. However, further studies
are needed to evaluate the long-term biocompatibility and potential interference with the optical and
physical properties of soft contact lenses used as a drug carrier [155].
4.4.1. Ionic Force-Sensitive Hydrogels in Topical Administration
Ion-activated hydrogels such as gellan gum or alginate are used to improve the efficiency of topical
administration [156]. These hydrogels can be instilled in liquid form in the eye and then undergo
gelification in response to pH changes or in the presence of certain ionic species contained in the tear
fluid [157]. These gel formulations are able to improve the pre-corneal persistence time of the drug [153].
Regarding the ocular delivery of timolol maleate (TM), Yu et al. could prepare ion-responsive in situ
gels containing liposomes by using deacetylated gellan gum (DGG). The produced drug-containing
liposomes had a round and uniform shape with a size of below 200 nm. Compared with a routine TM eye
drop formulation, the TM-containing liposomes showed a 1.93-fold increase in apparent permeability
coefficient, leading to a substantial improvement in the corneal penetration ability. Moreover, a longer
retention time on the corneal surface was recorded for the TM-loaded liposome-incorporated ion
sensitive in situ gels (TM L-ISG) in comparison with the eye drops. In vivo assessments in rabbit eyes
revealed the lack of irritation for ocular tissues. The authors reported the highest efficacy of TM L-ISG
at 30 min post-administration, which disappeared after 240 min. In 2015, Kesavan et al. published a
report on the usefulness of ion-activated mucoadhesive hydrogels based on gellan or sodium alginate
alone and combined with sodium carboxymethylcellulose (NaCMC) regarding the enhancement in
the gel bio-adhesion [158]. This formulation showed no irritation in rabbit eyes, without any sign of
inflammation. In addition, the results of in vivo antimicrobial evaluation of the muco-adhesive system
indicated its efficacy against bacterial keratitis in rabbit eyes.
There are several pharmacological agents that use hydrogel-based carriers to increase
bioavailability. Since these hydrogels can be delivered in the form of liquid eye drops, self-administration
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by patients is generally easy and well accepted. For example, Ranch et al. could successfully develop
a sustained DDS based on a gel of dexamethasone sodium phosphate (DXM) and chloramphenicol
(CHL) by using gellan gum in combination with carbopol 940, which could be a viable alternative to
conventional eye drops [159].
4.4.2. Thermo-Reactive Hydrogels for Intravitreal Injection
Thermo-reactive hydrogels are recognized as materials capable of swelling or de-swelling in
response to the temperature changes of the surrounding fluid. They are commonly categorized into
negatively thermosensitive, positively thermosensitive, and thermally reversible gels [160,161]. These
materials proved to be effective in the broad field of DDSs and, more specifically, in the context of
ocular drug release.
Scientific evidence showed that the main drawback of intravitreal anti-VEGF therapy is the
need for repeating the injections every 4–6 weeks over a total treatment duration of two years or
more. Thermo-reactive hydrogels are an ideal solution for the localized and prolonged delivery of
therapeutic drugs due to their phase transition capacity in response to temperature changes [162,163].
For example, the liquid-to-gel transition temperature of poly(N-isopropylacrylamide) (PNIPAAm)
is higher than the ambient temperature; thus, this hydrogel is liquid before being injected and then
transforms to a gel at body temperature. One of the main drawbacks of PNIPAAm hydrogels is
related to the limited amount of drug released in response to temperature changes. In the attempt to
address this issue, the use of PEG as a pore-forming agent was suggested to achieve macroporous
PNIPAAm hydrogels. For instance, Kang-Mieler et al. developed a thermo-reactive hydrogel by
crosslinking PNIPAAm with PEG diacrylate (PEG-DA) or PEG–poly-l-lactic acid (PLLA)-DA through
free-radical polymerization [164]. The obtained optically clear hydrogel could be easily injected
through small-size needles in the eye at room temperature. Once injected, this copolymer underwent
gelification and began to release the encapsulated pharmacological agents [165]. This system was
suitable to locally release proteins such as bevacizumab and ranibizumab for about one month and
did not induce any long-term side effects on retinal function [166]. It should be stated that applying
more highly cross-linked hydrogels could result in smaller pore sizes and longer release times [167].
However, hydrogels having small pore sizes become stiffer and more difficult to inject by small-gauge
needles, which makes it difficult to achieve a minimally invasive delivery system to the desired sites
(e.g., the vitreous cavity) [164]. Complete hydrogel degradation and drug release could be achieved
by incorporating a biodegradable segment in the copolymer [168]. The drug release time could be
extended by combining this hydrogel with degradable PLGA microspheres. In order to treat posterior
segment diseases, Xie et al. developed an injectable thermosensitive polymeric hydrogel based on
PLGA–PEG–PLGA to provide sustained release of Avastin® [169]. The system was prepared by the
sol–gel method, and a porous structure (pore size, 100–150 µm) was made. The sustained drug release
was recorded over a time of up to 14 days in vitro and no significant toxicity was observed against
retinal tissue. A single intravitreal injection of 1.5 mL of 20 wt.% Avastin®/PLGA–PEG–PLGA hydrogel
(18.75 mg Avastin®) in a rat model showed that the hydrogel apparently extended the Avastin® release
over time in vivo.
4.4.3. Cell-Releasing Hydrogels
In addition to releasing pharmacological agents, hydrogels can be used to provide cells for the cell
therapy of degenerative retinal diseases. Hydrogel-based cell release systems can play an important
role in promoting the survival, differentiation, and integration of delivered cells [170,171]. For example,
Ballios et al. developed a temperature-responsive biodegradable hyaluronic acid/methylcellulose
injectable hydrogel containing stem cells and this system was able to support the survival, proliferation,
and integration of stem cells in the degenerated retina [172].
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4.5. Combined Systems
A very interesting and effective strategy to overcome the major disadvantages of the various
drug release routes described above involves a combination of micro-/nanospheres or liposomes with
hydrogels in order to develop a complex, multifunctional system. The benefits obtained using this
approach may include a reduction of the initial burst release, a better confinement of carrier/drug in the
injection site, and an extension of the drug release time. Furthermore, a higher number of drugs and
their combinations can be simultaneously encapsulated in polymeric spheres and hydrogels. Recent
studies reported the suitability of PLGA microsphere/PLA–PEG–PLA hydrogel combined system for
applications in the treatment of ischemic vascular diseases, cartilage regeneration, and spinal cord
injury treatment [173].
In the context of ocular drug delivery, Lajavardi et al. [174] incorporated VIP-loaded liposomes
into hyaluronic acid hydrogel for the treatment of intravenously induced uveitis. This combination
could increase the drug residence/release time and proved to be effective in reducing eye inflammation.
Kang-Mieler et al. recently combined PNIPAAm injectable thermo-reactive hydrogel with PLGA
microspheres (ratio of 75:25) to create a microsphere–hydrogel ocular DDS that was able to encapsulate
ranibizumab or aflibercept and release both anti-VEGF drugs in a controlled way for about 200
days [175,176]. The drug concentration provided to the retina could be controlled depending on
the amount of microspheres suspended in the hydrogel. The efficacy of this system was tested
in the treatment of the laser-induced CNV murine model with the aim of replacing the current
monthly/bimonthly anti-VEGF therapeutic treatments [177].
5. Clinical Applications
A number of ocular DDSs are approved for routine clinical use or are somehow involved in
clinical trials; an overview is provided in Table 2.
Table 2. A short list of ocular drug delivery implants in clinical trials (from a market survey performed
in June 2020).
Brand Name Material Active Ingredient Dosage Form Indication
Vitrasert® PVA, EVA Ganciclovir Intravitreal implant
AIDS-related CMV
retinitis
Retisert® PVA, silicone Fluocinolone acetonide Intravitreal implant
Noninfectious uveitis,
posterior uveitis
Ozurdex® PLGA Dexamethasone Intravitreal implant
- DME
- CRVO
- BRVO
- Posterior uveitis
Iluvien® Polyimide Fluocinolone acetonide Intravitreal implant
- DME
- Wet AMD
Yutiq® Polyimide Fluocinolone acetonide Intravitreal implant
Chronic noninfectious
uveitis
DEXYCU®
Acetyl triethyl
citrate Dexamethasone Intraocular implant
Postoperative
inflammation
OTX- TKI/IVT Hydrogel TKIs; anti-VEGF Intravitrealimplants AMD
PDS Undisclosedpolymer Ranibizumab
Intravitreal
implants Wet AMD
Brimo PS
DDS® PLGA Brimonidine tartrate
Intravitreal
implants
- Pars plana vitrectomy
AMD
- Retinal detachment
- Geographic atrophy MD
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Table 2. Cont.
Brand Name Material Active Ingredient Dosage Form Indication
Rysmon® TG Methylcellulose Timolol maleate Eye drop Glaucoma
Betoptic S® Amberlite
®
IRP-69
Betaxolol Eye drop Glaucoma
Timoptic-XE® Gellan gum Timolol maleate Eye drop Glaucoma
AzaSite® Polycarbophil Azithromycin Eye drop Bacterial conjunctivitis
AzaSite Plus™ Polycarbophil Azithromycin/Dexamethasone(ISV-502) Eye drop Blepharoconjunctivitis
Lumitect™ Silicone matrix Cyclosporin Episcleral implant GVHD and cornealallograft rejection
I-vation™ TA PMMA/EVA Triamcinolone acetonide Intravitrealimplants DME
Visudyne® Liposome Verteporfin
Intravenous
injection Wet AMD
Durezol™ Emulsion Difluprednate Eye drop DME
Cortiject® Emulsion
Corticosteroid prodrug
(NOVA-63035)
Intravitreal
injection DME
Surodex™ PLGA, HPMC Dexamethasone Subconjunctivalimplants
Postoperative
inflammation following
cataract surgery
Lacrisert® HPC HPC
Cul-de-sac
implants
Moderate to severe dry eye
syndrome, including
keratitis sicca
Murocel®
Methylcellulose
(MC) PEG, PVA, Povidone Eye drop Dried eyes
Celluvisc® CMC sodium Carmellose sodium Eye drop Dried eyes
Ultra Tears® HPMC PEG, PVA, Povidone Eye drop Dried and irritated eyes
AIDS: acquired immune deficiency syndrome, AMD: age-related macular degeneration, BRVO: branch retinal
vein occlusion, CMC: carboxy methyl cellulose, CMV: cytomegalovirus, CRVO: central retinal vein occlusion,
DME: diabetic macular edema, EVA: ethylene–vinyl acetate copolymer, GVHD: graft versus host diseases, HPC:
hydroxypropyl cellulose, HPMC: hydroxypropyl methylcellulose, PLGA: poly(lactide-co-glycolide), PMMA:
poly(methylmethacrylate), PEG: poly ethylene glycol, PVA: poly(vinyl alcohol), TKI: tyrosine kinase inhibitor, VEGF:
vascular endothelial growth factor.
Some further details about the most challenging applications are given in the sections below.
5.1. Glaucoma
Glaucoma is a pathology generally characterized by the increase in IOP, with consequent damage
to the optic nerve which can lead to blindness [178]. The pressure increase is often due to the insufficient
drainage of the aqueous humor through the physiological pathways. Depending on a number of
factors (e.g., stage of the pathology, patient’s co-operation, and general clinical situation), IOP reduction
can be obtained through the application of local (eye drops) or systemic hypotonic drugs, laser-based
para-surgical treatments, or surgical approaches that aim at improving aqueous humor drainage by
the creation of alternative pathways. In recent years, new therapeutic horizons were opened through
the use of novel biomaterials and DDSs.
The surgical treatment of glaucoma aims at reducing the IOP values, which can be achieved by
implanting drainage devices in the eyeball. The reason behind the high failure rate of this type of
surgery is postoperative fibrosis, which occurs after 3–5 years due to excessive scarring in about 30%
of cases [179]. Ayala et al. [180,181] studied the effect of various biomaterials on the formation and
degree of fibrosis in experimental animal models. Blake et al. [182] pioneered the use of pHEMA
hydrogel incorporating the anti-fibrotic drug mitomycin-C. The polymer was first washed in order
to remove low-molecular-weight toxic substances (polymerization residues), and mitomycin-C was
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then introduced into the matrix. pHEMA activated the release of the drug in contact with water;
this mechanism is very suitable for glaucoma surgery as the water-based aqueous humor flows to
the surgical site where the mitomycin-C is released to reduce fibrosis. The results obtained in vitro
using human conjunctival fibroblasts revealed that mitomycin-C inhibited cell proliferation in a
dose-dependent way. Sahiner et al. [183] inserted mitomycin-C-loaded pHEMA discs onto Ahmed’s
glaucoma valves (AGVs) implanted in rabbits and observed that the drug release occurred upon
hydrogel swelling due to contact with aqueous humor. Histological data showed the formation of a
thinner fibrous capsule in the animals receiving the DDS, which was also not damaged by ultraviolet
(UV) sterilization processes (Figure 5).
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Hovakimyan et al. [184] developed a novel glaucoma drainage device incorporating a local DDS
to increase safety and efficacy following implantation in the suprachoroidal space. Two different
polymers were used in this work, i.e., poly(3-hydroxybutyrate) (P3HB) and poly(4-hydroxybutyrate)
(P4HB), in which mitomycin-C or paclitaxel was incorporated. Drug-loaded polymeric films were
attached to small silicone tubes to create the DDS-incorporating drainage system. These devices were
then implanted in the suprachoroidal space of rabbits, and the IOP was periodically measured in a
non-invasive way. After six weeks, the rabbits were sacrificed, and the enucleated eyes were examined
by optical coherence tomography of the anterior segment (OCT), magnetic resonance imaging (MRI),
and histological assessment. The results confirmed that an effective reduction of the IOP was achieved
in vivo; in vitro release of mitomycin-C was faster from both polymers as compared to paclitaxel,
while the release from the matrix of P3HB was slower for both drugs. No pronounced fibrosis was
observed in any of the groups, but both drugs caused damage to the retina. In order to avoid these
negative effects, it will be necessary to use or find new drugs with lower cytotoxicity; furthermore,
future studies should be focused on evaluating the long-term efficacy of anti-fibrotic agents.
Implantation of an AGV, which was cleared for clinical use by the FDA in 1993, is perhaps the
preferred surgical treatment for glaucoma. Clinical studies reported that the use of AGV is associated
with a relatively lower incidence of postoperative complications compared to other aqueous humor
drainage devices [185,186]. The success rate of AGV implantation is about 80% one year after surgery,
but the five-year success rate drops to 40–50% due to postoperative bleb scarring (i.e., the bleb loses
its function). Administration of 5-fluorouracil (5-Fu) is effective to inhibit bleb scarring; as a single
application of 5-Fu can reduce postoperative bleb fibrosis only for a limited time period [187], there is
the need for multiple local injections that, however, increase the risks of corneal damage, bleb leakage,
ocular hypotony, intraocular infection, and other side effects [188]. Therefore, the development of a
DDS to be combined with AGV is key to improve the success rate of glaucoma treatment. Bi et al. [189]
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conducted a study on the possible inhibition of postoperative bleb scarring in rabbit eyes by a
(5-Fu)-loaded polycaprolactone (PCL) film attached to AGV. Eighteen New Zealand white rabbits were
randomly and evenly divided into three different groups, i.e., group A (combined application of the
5-Fu–PCL prolonged-release film and the AGV), B (local 5-Fu infiltration and AGV implantation), and
C (AGV only). Preliminary in vitro tests revealed that the 5-Fu–PCL sustained-release film maintained
a release concentration range of 13.7 ± 0.12 to 37.41 ± 0.47 µg/mL over three months. In vivo tests
showed the presence of diffuse blebs with ridges in all eyes of group A, two blebs in group B, and
no bleb in group C. The postoperative IOP of groups A and C stabilized at 6.33–8.67 mmHg and
7.55–10.02 mmHg, respectively. Histopathological examination showed that the fibrous tissue thickness
of the blebs in group A was significantly thinner than that of the other groups, further supporting the
suitability of the 5-Fu–PCL DDS in promoting the inhibition of bleb scarring after AGV implantation.
5.2. Corneal Transplantation
Immunological allograft rejection is considered the major cause of corneal graft failure following
transplantation (keratoplasty) [190]. The exact mechanisms leading to graft rejection are not yet fully
understood; it is believed that, with regard to the epithelial and stromal rejection, a vascularized
cornea may deliver effector cells to the corneal grafts through the corneal limbus pathway, while, with
regard to the endothelial rejection, leukocytes are likely to exit from the iris ciliary body and pass
through the anterior chamber before targeting the corneal grafts [191,192]. Therefore, the intraocular
immunosuppressive reaction can indeed influence the development of immune reaction and the
long-term corneal graft survival.
Shi’s research team reported that PLGA/PCL DDSs releasing cyclosporine, an immunosuppressive
drug, were effective in decreasing the rejection rate and prolonging the survival time of corneal
allografts in both rabbits and human patients [193,194]. The mechanism involved was thought to be
related to the general improvement of the immune microenvironment in the corneal allograft, iris
ciliary body, and aqueous humor (Figure 6).
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5.3. Macular Edema
Retinal pathologies affecting the macular area (maculopathies) impressively increased in the
world population over the last few decades due to the increase in people’s average life, which involves
an increase of age-related degenerative diseases, as well as metabolic chronic pathologies such as
diabetes, which is a major responsible of macular edema and diabetic retinopathy [195].
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At present, there are a couple of implantable DDSs (Ozurdex and Iluvien) that are mainly used in
the treatment of macular edema.
Ozurdex is a biodegradable implant pre-loaded with 0.7 mg of dexamethasone. It is injected into
the vitreous with a 22-gauge applicator without the need for suturing. This DDS is based on a PLGA
matrix which slowly degrades into lactic acid and glycolic acid allowing the prolonged release of
dexamethasone over a period of six months, without leaving any residues in the eye (the degradation
products are water and carbon dioxide). Ozurdex is clinically approved for the treatment of macular
edema following retinal vascular occlusion, diabetic macular edema, inflammation of the posterior
segment, and uveitis [196–199].
Iluvien® (Alimera Sciences, Inc., USA) is a multi-polymeric mini-implant for intravitreal injection
consisting of a 3.5 mm (length) × 0.37 mm (diameter) polyamide tube containing 190 µg of fluocinolone
acetonide (FA) loaded in a poly(vinyl alcohol) (PVA) matrix; one end of the tube is capped with PVA
and the other end is sealed with silicone adhesive. The end capped with PVA is permeable to aqueous
fluids and controls the release of FA upon hydration of the PVA matrix. This DDS is injected through
the pars plana without the need for suturing. It was estimated that 0.2 µg of drug is released every day
for about three years; the drug release stabilizes after an initial period. The release constant is slightly
higher at the beginning, but in the long term it reaches a stable value. On the basis of clinical studies,
this DDS obtained clearance for commercialization in Europe and the United States of America (USA)
for the treatment of chronic diabetic macular edema when it is irresponsive to other therapies [200,201].
Apart from Ozurdex and Iluvien, other experimental DDSs were tested for the treatment of
macular edema. For example, Prata et al. [202] tested dexamethasone-releasing biodegradable implants
based on PCL or PLA prepared by solvent-casting or simple casting. In general, PLA-based devices
released only a fraction of the immobilized drug in the first week and, then, drug delivery was
negligible. On the contrary, drug was released in a controlled way from PCL-based devices over two
months in vitro. The preparation method had little influence on the release profiles. However, simple
casting allowed obtaining a more uniform distribution of dexamethasone in the polymer matrix and,
therefore, was selected as the prepared fabrication method, also considering that this route was easier
and avoided the use of potentially toxic organic solvents. It was also suggested a minimum theoretical
drug-to-polymer ratio of 0.25 for PCL-based implants.
Fialho et al. [203] showed that PCL-based implants allow a prolonged release of dexamethasone to
be achieved in vitro, as well as a good short-term intraocular tolerance in rabbit eyes. Gaudana et al. [7]
also reported a prolonged release of dexamethasone from PCL implants (25% of the drug over 21
weeks).
5.4. Maculopathy
Protein- and peptide-based therapies were recently introduced for the treatment of AMDs. For
this purpose, anti-VEGF therapeutics such as pegaptanib (Macugen®), ranibizumab (Lucentis®),
aflibercept (Eylea®), and bevacizumab (Avastin®) are typically injected intravitreally.
These large molecules have a potent anti-angiogenic effect and low toxicity as compared to smaller
molecules, but they are sensitive to physical and chemical degradation, have a short half-life in vivo,
and suffer from difficult distribution to the target site. In fact, their therapeutic efficacy is reduced by
their high molecular weight and complex structure, which lead to difficult passage through the cell
membranes and attack by the cells of the endothelial reticular system [204].
Various in situ gelling materials proved to be potentially safe for use as intravitreal DDSs.
Tyagi et al. [205] developed an in situ light-activated gelling system based on PCL dimethacrylate/
HEMA that allowed the prolonged release of bevacizumab after being injected into the suprachoroidal
space. Wang et al. [206] studied the in vitro release of bevacizumab from a heat-sensitive gel based
on poly(2-ethyl-2-oxazoline)–PCL–poly(2-ethyl-2-oxazoline) (PEOz–PCL–PEOz) triblock copolymer
which allowed achieving a drug release time of 18 days. PLGA-based hydrogels also showed promise
for the intravitreal release of triamcinolone acetonide [207].
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6. Conclusions
The regulation of ocular cell/tissue response by controlled drug release still remains a challenge.
Key aspects to take into account concern both the administration route/DDS used and the drug in itself.
While selecting the DDS material, the placement site should be carefully considered to find out the
possible factors accelerating or inhibiting the delivery (e.g., physiological constraints, tissue barriers,
blood/fluid flow). Moreover, the inherent physico-chemical properties of the drug to be delivered should
be taken into account, including molecular size/weight, charge, and hydrophobicity/hydrophilicity.
If the administration route involves injection, the drug carrier must deform under shear stresses
without losing its integrity. An ideal DDS should also be fully biodegradable without leaving any
toxic residues in the ocular tissues. Finally, sterilization procedures should not alter the properties of
carrier and drug; as this could be tricky for organic materials like pharmaceutics and polymers, such a
problem should be somehow considered at the design stage.
In general, extended drug release by using DDSs is a highly attractive alternative to traditional
methods of ocular drug administration (e.g., eye drops) as it allows bypassing ocular tissue barriers,
minimizing the need for the patient’s co-operation (which can be sometimes problematic), and
decreasing the frequency of surgical interventions (e.g., intravitreal injections). At present, an ideal
biomaterial for making DDSs does not exist but each option has advantages and disadvantages with
regard to the given application. PLGA is suitable for preparing resorbable micro- and nanospheres and
can be variously combined with other polymers, such as polysaccharides, to modulate the degradation
rate. Liposomes are deformable and can easily pass through the hydrophobic ocular tissue barriers;
furthermore, they can extend the drug half-life. Hydrogels are perhaps the most versatile systems being
injectable, stimuli-responsive (e.g., they undergo gelification upon temperature increase), and properly
degradable depending on the polymer formulation. Combined DDSs, such as hydrogels embedding
micro- or nanospheres, show superiority over single-material DDSs and have the potential to further
increase the control on drug release kinetics, extend the total time of release, and improve drug
bioavailability. Finally, the possibility of combining or replacing the use of drugs with the therapeutic
effects elicited by metallic ions released from biomaterials deserves to be explored in the future, in the
attempt of overcoming some drawbacks related to biomolecules (e.g., thermal degradation, bacterial
resistance to antibiotics).
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